REAL-WORLD COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB

被引：0
|
作者：
Rogers, K. A. [1 ]
Qureshi, Z. P. [2 ]
Ding, Z. [2 ]
Emond, B. [3 ]
Gogna, P. [3 ]
Lafeuille, M. H. [3 ]
Bokun, A. [2 ]
Fradley, M. [4 ,5 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Hosp Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Thalheimer Ctr Cardiooncol, Philadelphia, PA USA
[5] Hosp Univ Penn, Perelman Sch Med, Div Cardiol, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE70
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [1] Real-world healthcare resource utilization and costs in patients with chronic lymphocytic leukemia: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra
    Wilson, Kathleen
    Thompson, Stephen
    Choudhry, Azhar
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 623 - 628
  • [2] Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line
    Lu Xiaoxiao
    Bruno, Emond
    Laura, Morrison
    Frederic, Kinkead Frederic
    Patrick, Lefebvre
    Helene, Marie-Lafeuille
    Wasiulla, Khan
    Wu Linda
    Zaina, P. Qureshi Zaina P.
    Ryan, Jacobs
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S26 - S26
  • [3] Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Jacobs, Ryan
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 2073 - 2084
  • [4] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [5] Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie
    Chen, Yan
    Duh, Mei Sheng
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    [J]. BLOOD ADVANCES, 2023, 7 (16) : 4291 - 4301
  • [6] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE AMONG US MEDICARE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING FIRST-LINE IBRUTINIB VS CHEMOIMMUNOTHERAPY
    Huang, Q.
    Emond, B.
    Lafeuille, M. H.
    Gupta, D.
    Lefebvre, P.
    Sundaram, M.
    Mato, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S44 - S45
  • [7] Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine plus Rituximab
    Irwin, Debra
    Zhang, Lu
    Wilson, Kathleen
    Hoehn, Gerard
    Szabo, Erika
    Tang, Boxiong
    [J]. BLOOD, 2018, 132
  • [8] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    [J]. BLOOD, 2022, 140 : 10911 - 10912
  • [9] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    [J]. Advances in Therapy, 2022, 39 : 3292 - 3307
  • [10] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
12345